VIAF

Virtual International Authority File

Search

Leader     00000nz a2200037n 45 0
001     WKP|Q44323994  (VIAF cluster)  (Authority/Source Record)
003     WKP
005     20241121000147.0
008     241121nneanz||abbn n and d
035 ‎‡a  (WKP)Q44323994‏
024 ‎‡a  0000-0002-6689-7856‏ ‎‡2  orcid‏
024 ‎‡a  7201744055‏ ‎‡2  scopus‏
035 ‎‡a  (OCoLC)Q44323994‏
100 0 ‎‡a  Marisa B. Marques‏ ‎‡9  ast‏ ‎‡9  sl‏
375 ‎‡a  2‏ ‎‡2  iso5218‏
400 0 ‎‡a  Marisa B. Marques‏ ‎‡c  researcher‏ ‎‡9  en‏
400 0 ‎‡a  Marisa B. Marques‏ ‎‡c  onderzoeker‏ ‎‡9  nl‏
400 0 ‎‡a  Marisa B. Marques‏ ‎‡c  investigadora‏ ‎‡9  es‏
670 ‎‡a  Author's A new "initial" case of transfusion-related acute lung injury‏
670 ‎‡a  Author's A safe and effective management strategy for BCVI.‏
670 ‎‡a  Author's Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices‏
670 ‎‡a  Author's Acquired von Willebrand's disease in myelofibrosis and essential thrombocythemia‏
670 ‎‡a  Author's Acute transient leukopenia as a sign of TRALI‏
670 ‎‡a  Author's Age of transfused blood: an independent predictor of mortality despite universal leukoreduction‏
670 ‎‡a  Author's An Adolescent With a History of Menorrhagia‏
670 ‎‡a  Author's An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura.‏
670 ‎‡a  Author's Anti-Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation‏
670 ‎‡a  Author's Apheresis in developing countries around the World‏
670 ‎‡a  Author's Apheresis research-more abstracts should be published as full manuscripts to provide more evidence for clinical practice guidelines‏
670 ‎‡a  Author's Category IV indications for therapeutic apheresis: ASFA fourth special issue‏
670 ‎‡a  Author's Clinical pathology consultation improves coagulation factor utilization in hospitalized adults‏
670 ‎‡a  Author's Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients‏
670 ‎‡a  Author's Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange‏
670 ‎‡a  Author's Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients - an economic evaluation.‏
670 ‎‡a  Author's Decoding laboratory test names: a major challenge to appropriate patient care‏
670 ‎‡a  Author's Defining the effects of storage on platelet bioenergetics: The role of increased proton leak‏
670 ‎‡a  Author's Duration of red cell storage influences mortality after trauma‏
670 ‎‡a  Author's Educating medical students in laboratory medicine: a proposed curriculum‏
670 ‎‡a  Author's Erythrocyte storage increases rates of NO and nitrite scavenging: implications for transfusion-related toxicity‏
670 ‎‡a  Author's Establishing an institutional therapeutic apheresis registry‏
670 ‎‡a  Author's Estimating blood needs for very-low-birth-weight infants‏
670 ‎‡a  Author's Etiology of Pulmonary Thromboembolism in the Absence of Commonly Recognized Risk Factors‏
670 ‎‡a  Author's Extracorporeal photopheresis: technique, established and novel indications‏
670 ‎‡a  Author's Fat Embolism Syndrome Secondary to Bone Marrow Necrosis in Patients with Hemoglobinopathies‏
670 ‎‡a  Author's First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur?‏
670 ‎‡a  Author's Free flap failure secondary to dual thrombophilia‏
670 ‎‡a  Author's Genotypic investigation of multidrug-resistant Acinetobacter baumannii infections in a medical intensive care unit‏
670 ‎‡a  Author's Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis‏
670 ‎‡a  Author's High Percentage of Evanescent Red Cell Antibodies in Patients with Sickle Cell Disease Highlights Need for a National Antibody Database‏
670 ‎‡a  Author's How we closed the gap between red blood cell utilization and whole blood collections in our institution‏
670 ‎‡a  Author's Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura‏
670 ‎‡a  Author's Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin‏
670 ‎‡a  Author's Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura‏
670 ‎‡a  Author's Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study‏
670 ‎‡a  Author's Inside Out: Bone Marrow Necrosis and Fat Embolism Complicating Sickle-β+ Thalassemia.‏
670 ‎‡a  Author's Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?‏
670 ‎‡a  Author's Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial‏
670 ‎‡a  Author's Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura‏
670 ‎‡a  Author's Membrane attack complex generation increases as a function of time in stored blood‏
670 ‎‡a  Author's Metabolic plasticity in resting and thrombin activated platelets‏
670 ‎‡a  Author's Modification of platelet proteins by 4-hydroxynonenal: Potential Mechanisms for inhibition of aggregation and metabolism‏
670 ‎‡a  Author's Multiorgan failure and bone marrow necrosis in three adults with sickle cell-β+ -thalassemia‏
670 ‎‡a  Author's Novel ADAMTS13 mutations in an obstetric patient with Upshaw-Schulman syndrome‏
670 ‎‡a  Author's Out with the bad and in with the good; red cell exchange, white cell reduction, and platelet reduction‏
670 ‎‡a  Author's Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).‏
670 ‎‡a  Author's Pathology Consultation on the Laboratory Evaluation of Thrombophilia‏
670 ‎‡a  Author's Patient Blood Management as Standard of Care‏
670 ‎‡a  Author's Perceptions about blood transfusion: a survey of surgical patients and their anesthesiologists and surgeons‏
670 ‎‡a  Author's Periprocedural management of patients on anticoagulants‏
670 ‎‡a  Author's Peroxiredoxin-2 recycling is inhibited during erythrocyte storage‏
670 ‎‡a  Author's Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results‏
670 ‎‡a  Author's Photopheresis in solid organ transplant rejection‏
670 ‎‡a  Author's Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults‏
670 ‎‡a  Author's Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury‏
670 ‎‡a  Author's Predicting storage-dependent damage to red blood cells using nitrite oxidation kinetics, peroxiredoxin-2 oxidation, and hemoglobin and free heme measurements‏
670 ‎‡a  Author's Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience‏
670 ‎‡a  Author's Primary care physicians and the laboratory: now and the future‏
670 ‎‡a  Author's Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization‏
670 ‎‡a  Author's Red blood cell washing, nitrite therapy, and antiheme therapies prevent stored red blood cell toxicity after trauma-hemorrhage‏
670 ‎‡a  Author's Refractory thrombocytopenia and positive platelet crossmatches without HLA or platelet-specific antibodies‏
670 ‎‡a  Author's Rejection With Hemodynamic Compromise: Objective Evidence for Efficacy of Photopheresis‏
670 ‎‡a  Author's Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab‏
670 ‎‡a  Author's Rhesus Immune Globulin Dosing in the Obesity Epidemic Era‏
670 ‎‡a  Author's Screening With the Activated Protein C Resistance Assay Yields Significant Savings in a Patient Population With Low Prevalence of Factor V Leiden‏
670 ‎‡a  Author's Single-center experience with extracorporeal photopheresis in pediatric heart transplantation‏
670 ‎‡a  Author's Society for the Advancement of Patient Blood Management and Anesthesia & Analgesia: A New Collaboration and Home for Blood Management Research‏
670 ‎‡a  Author's Successful pulmonary thromboendarterectomy in a patient with sickle cell disease treated with a single preoperative red blood cell exchange‏
670 ‎‡a  Author's Teaching medical students basic principles of laboratory medicine‏
670 ‎‡a  Author's The American Society for Apheresis (ASFA) is pleased to offer a Qualification in Apheresis (QIA) in partnership with The Board of Certification (BOC) of the American Society for Clinical Pathology (ASCP) starting in January of 2016!‏
670 ‎‡a  Author's The Clinical Pathologist as Consultant‏
670 ‎‡a  Author's The isolated prolonged PTT.‏
670 ‎‡a  Author's The level of complement activation fragments is higher in red blood cell units than segments‏
670 ‎‡a  Author's The success of our patient blood management program depended on an institution-wide change in transfusion practices‏
670 ‎‡a  Author's The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network‏
670 ‎‡a  Author's The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections.‏
670 ‎‡a  Author's Therapeutic Apheresis Academy 2013: beyond borders‏
670 ‎‡a  Author's Therapeutic plasma exchange for intractable pruritus secondary to primary sclerosing cholangitis‏
670 ‎‡a  Author's Therapeutic plasma exchange rapidly improves cardiac allograft function in patients with presumed antibody-mediated rejection‏
670 ‎‡a  Author's Thrombelastographic measures of clot propagation: a comparison of alpha with the maximum rate of thrombus generation‏
670 ‎‡a  Author's Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research‏
670 ‎‡a  Author's Thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia: two unique causes of life-threatening thrombocytopenia‏
670 ‎‡a  Author's Thrombotic thrombocytopenic purpura does not show seasonal variation in Alabama‏
670 ‎‡a  Author's Transfusion and Pneumonia in the Trauma Intensive Care Unit: An Examination of the Temporal Relationship‏
670 ‎‡a  Author's Transfusion medicine illustrated. Massive hemolysis due to thrombotic thrombocytopenic purpura in a patient with AIDS.‏
670 ‎‡a  Author's Transfusion medicine illustrated. Systemic neutrophilic aggregates in transfusion-related acute lung injury.‏
670 ‎‡a  Author's Transfusion-related acute lung injury: past, present, and future‏
670 ‎‡a  Author's Transfusions in the Less Severely Injured: Does Age of Transfused Blood Affect Outcomes?‏
670 ‎‡a  Author's Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature‏
670 ‎‡a  Author's Update on extracorporeal photopheresis in heart and lung transplantation‏
670 ‎‡a  Author's Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity.‏
670 ‎‡a  Author's von Willebrand Disease Laboratory Diagnosis‏
670 ‎‡a  Author's Zika Virus and Patient Blood Management‏
909 ‎‡a  (scopus) 7201744055‏ ‎‡9  1‏
909 ‎‡a  (orcid) 0000000266897856‏ ‎‡9  1‏
919 ‎‡a  1symptomsinpatientswiththromboticthrombocytopenicpurpurawhataretheyandwhendotheyoccur‏ ‎‡A  First symptoms in patients with thrombotic thrombocytopenic purpura: what are they and when do they occur?‏ ‎‡9  1‏
919 ‎‡a  fatembolismsyndromesecondarytobonemarrownecrosisinpatientswithhemoglobinopathies‏ ‎‡A  Fat Embolism Syndrome Secondary to Bone Marrow Necrosis in Patients with Hemoglobinopathies‏ ‎‡9  1‏
919 ‎‡a  extracorporealphotopheresistechniqueestablishedandnovelindications‏ ‎‡A  Extracorporeal photopheresis: technique, established and novel indications‏ ‎‡9  1‏
919 ‎‡a  etiologyofpulmonarythromboembolismintheabsenceofcommonlyrecognizedriskfactors‏ ‎‡A  Etiology of Pulmonary Thromboembolism in the Absence of Commonly Recognized Risk Factors‏ ‎‡9  1‏
919 ‎‡a  estimatingbloodneedsforverylowbirthweightinfants‏ ‎‡A  Estimating blood needs for very-low-birth-weight infants‏ ‎‡9  1‏
919 ‎‡a  establishinganinstitutionaltherapeuticapheresisregistry‏ ‎‡A  Establishing an institutional therapeutic apheresis registry‏ ‎‡9  1‏
919 ‎‡a  erythrocytestorageincreasesratesofnoandnitritescavengingimplicationsfortransfusionrelatedtoxicity‏ ‎‡A  Erythrocyte storage increases rates of NO and nitrite scavenging: implications for transfusion-related toxicity‏ ‎‡9  1‏
919 ‎‡a  educatingmedicalstudentsinlaboratorymedicineaproposedcurriculum‏ ‎‡A  Educating medical students in laboratory medicine: a proposed curriculum‏ ‎‡9  1‏
919 ‎‡a  durationofredcellstorageinfluencesmortalityaftertrauma‏ ‎‡A  Duration of red cell storage influences mortality after trauma‏ ‎‡9  1‏
919 ‎‡a  definingtheeffectsofstorageonplateletbioenergeticstheroleofincreasedprotonleak‏ ‎‡A  Defining the effects of storage on platelet bioenergetics: The role of increased proton leak‏ ‎‡9  1‏
919 ‎‡a  decodinglaboratorytestnamesamajorchallengetoappropriatepatientcare‏ ‎‡A  Decoding laboratory test names: a major challenge to appropriate patient care‏ ‎‡9  1‏
919 ‎‡a  cryoprecipitateahfvsfibrinogenconcentratesforfibrinogenreplacementinacquiredbleedingpatientsaneconomicevaluation‏ ‎‡A  Cryoprecipitate AHF vs. fibrinogen concentrates for fibrinogen replacement in acquired bleeding patients - an economic evaluation.‏ ‎‡9  1‏
919 ‎‡a  continuousinfusionofcalciumgluconatein5albuminissafeandpreventsmosthypocalcemicreactionsduringtherapeuticplasmaexchange‏ ‎‡A  Continuous infusion of calcium gluconate in 5% albumin is safe and prevents most hypocalcemic reactions during therapeutic plasma exchange‏ ‎‡9  1‏
919 ‎‡a  complianceratesandoutcomesassociatedwitharestrictivetransfusionpolicyingynecologiconcologypatients‏ ‎‡A  Compliance rates and outcomes associated with a restrictive transfusion policy in gynecologic oncology patients‏ ‎‡9  1‏
919 ‎‡a  clinicalpathologyconsultationimprovescoagulationfactorutilizationinhospitalizedadults‏ ‎‡A  Clinical pathology consultation improves coagulation factor utilization in hospitalized adults‏ ‎‡9  1‏
919 ‎‡a  category4indicationsfortherapeuticapheresisasfa4specialissue‏ ‎‡A  Category IV indications for therapeutic apheresis: ASFA fourth special issue‏ ‎‡9  1‏
919 ‎‡a  apheresisresearchmoreabstractsshouldbepublishedasfullmanuscriptstoprovidemoreevidenceforclinicalpracticeguidelines‏ ‎‡A  Apheresis research-more abstracts should be published as full manuscripts to provide more evidence for clinical practice guidelines‏ ‎‡9  1‏
919 ‎‡a  apheresisindevelopingcountriesaroundtheworld‏ ‎‡A  Apheresis in developing countries around the World‏ ‎‡9  1‏
919 ‎‡a  antibloodgroupantibodiesinintravenousimmunoglobulinmaycomplicateinterpretationofantibodytitersinaboincompatibletransplantation‏ ‎‡A  Anti-Blood Group Antibodies in Intravenous Immunoglobulin May Complicate Interpretation of Antibody Titers in ABO-Incompatible Transplantation‏ ‎‡9  1‏
919 ‎‡a  inquiryintotherelationshipbetweenabobloodgroupandthromboticthrombocytopenicpurpura‏ ‎‡A  An inquiry into the relationship between ABO blood group and thrombotic thrombocytopenic purpura.‏ ‎‡9  1‏
919 ‎‡a  adolescentwithahistoryofmenorrhagia‏ ‎‡A  An Adolescent With a History of Menorrhagia‏ ‎‡9  1‏
919 ‎‡a  ageoftransfusedbloodanindependentpredictorofmortalitydespiteuniversalleukoreduction‏ ‎‡A  Age of transfused blood: an independent predictor of mortality despite universal leukoreduction‏ ‎‡9  1‏
919 ‎‡a  acutetransientleukopeniaasasignoftrali‏ ‎‡A  Acute transient leukopenia as a sign of TRALI‏ ‎‡9  1‏
919 ‎‡a  acquiredvonwillebrandsdiseaseinmyelofibrosisandessentialthrombocythemia‏ ‎‡A  Acquired von Willebrand's disease in myelofibrosis and essential thrombocythemia‏ ‎‡9  1‏
919 ‎‡a  absorbanceandredoxbasedapproachesformeasuringfreehemeandfreehemoglobininbiologicalmatrices‏ ‎‡A  Absorbance and redox based approaches for measuring free heme and free hemoglobin in biological matrices‏ ‎‡9  1‏
919 ‎‡a  safeandeffectivemanagementstrategyforbcvi‏ ‎‡A  A safe and effective management strategy for BCVI.‏ ‎‡9  1‏
919 ‎‡a  genotypicinvestigationofmultidrugresistantacinetobacterbaumanniiinfectionsinamedicalintensivecareunit‏ ‎‡A  Genotypic investigation of multidrug-resistant Acinetobacter baumannii infections in a medical intensive care unit‏ ‎‡9  1‏
919 ‎‡a  guidelinesontheuseoftherapeuticapheresisinclinicalpracticeevidencebasedapproachfromtheapheresisapplicationscommitteeoftheamericansocietyforapheresis‏ ‎‡A  Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis‏ ‎‡9  1‏
919 ‎‡a  highpercentageofevanescentredcellantibodiesinpatientswithsicklecelldiseasehighlightsneedforanationalantibodydatabase‏ ‎‡A  High Percentage of Evanescent Red Cell Antibodies in Patients with Sickle Cell Disease Highlights Need for a National Antibody Database‏ ‎‡9  1‏
919 ‎‡a  howweclosedthegapbetweenredbloodcellutilizationandwholebloodcollectionsinourinstitution‏ ‎‡A  How we closed the gap between red blood cell utilization and whole blood collections in our institution‏ ‎‡9  1‏
919 ‎‡a  humanneutrophilpeptidesandcomplementfactorbbinpathogenesisofacquiredthromboticthrombocytopenicpurpura‏ ‎‡A  Human neutrophil peptides and complement factor Bb in pathogenesis of acquired thrombotic thrombocytopenic purpura‏ ‎‡9  1‏
919 ‎‡a  immunemediatedthrombocytopeniaresultingfromsensitivitytooxaliplatin‏ ‎‡A  Immune-mediated thrombocytopenia resulting from sensitivity to oxaliplatin‏ ‎‡9  1‏
919 ‎‡a  increasedtroponin1isassociatedwithfataloutcomeinacquiredthromboticthrombocytopenicpurpura‏ ‎‡A  Increased troponin I is associated with fatal outcome in acquired thrombotic thrombocytopenic purpura‏ ‎‡9  1‏
919 ‎‡a  influenceofkidneyfunctiononriskofsupratherapeuticinternationalnormalizedratiorelatedhemorrhageinwarfarinusersaprospectivecohortstudy‏ ‎‡A  Influence of kidney function on risk of supratherapeutic international normalized ratio-related hemorrhage in warfarin users: a prospective cohort study‏ ‎‡9  1‏
919 ‎‡a  insideoutbonemarrownecrosisandfatembolismcomplicatingsickleβ+thalassemia‏ ‎‡A  Inside Out: Bone Marrow Necrosis and Fat Embolism Complicating Sickle-β+ Thalassemia.‏ ‎‡9  1‏
919 ‎‡a  istherapeuticplasmaexchangeindicatedforpatientswithgemcitabineinducedhemolyticuremicsyndrome‏ ‎‡A  Is therapeutic plasma exchange indicated for patients with gemcitabine-induced hemolytic uremic syndrome?‏ ‎‡9  1‏
919 ‎‡a  makingthaweduniversaldonorplasmaavailablerapidlyformassivelybleedingtraumapatientsexperiencefromthepragmaticrandomizedoptimalplateletsandplasmaratiospropprtrial‏ ‎‡A  Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial‏ ‎‡9  1‏
919 ‎‡a  managementofapatientwithhivinfectioninducedanemiaandthrombocytopeniawhopresentedwiththromboticthrombocytopenicpurpura‏ ‎‡A  Management of a patient with HIV infection-induced anemia and thrombocytopenia who presented with thrombotic thrombocytopenic purpura‏ ‎‡9  1‏
919 ‎‡a  newinitialcaseoftransfusionrelatedacutelunginjury‏ ‎‡A  A new "initial" case of transfusion-related acute lung injury‏ ‎‡9  1‏
919 ‎‡a  membraneattackcomplexgenerationincreasesasafunctionoftimeinstoredblood‏ ‎‡A  Membrane attack complex generation increases as a function of time in stored blood‏ ‎‡9  1‏
919 ‎‡a  metabolicplasticityinrestingandthrombinactivatedplatelets‏ ‎‡A  Metabolic plasticity in resting and thrombin activated platelets‏ ‎‡9  1‏
919 ‎‡a  modificationofplateletproteinsby4hydroxynonenalpotentialmechanismsforinhibitionofaggregationandmetabolism‏ ‎‡A  Modification of platelet proteins by 4-hydroxynonenal: Potential Mechanisms for inhibition of aggregation and metabolism‏ ‎‡9  1‏
919 ‎‡a  multiorganfailureandbonemarrownecrosisin3adultswithsicklecellβ+thalassemia‏ ‎‡A  Multiorgan failure and bone marrow necrosis in three adults with sickle cell-β+ -thalassemia‏ ‎‡9  1‏
919 ‎‡a  noveladamts13mutationsinanobstetricpatientwithupshawschulmansyndrome‏ ‎‡A  Novel ADAMTS13 mutations in an obstetric patient with Upshaw-Schulman syndrome‏ ‎‡9  1‏
919 ‎‡a  outwiththebadandinwiththegoodredcellexchangewhitecellreductionandplateletreduction‏ ‎‡A  Out with the bad and in with the good; red cell exchange, white cell reduction, and platelet reduction‏ ‎‡9  1‏
919 ‎‡a  pathologyconsultationonthediagnosisandtreatmentofthromboticmicroangiopathiestmas‏ ‎‡A  Pathology Consultation on the Diagnosis and Treatment of Thrombotic Microangiopathies (TMAs).‏ ‎‡9  1‏
919 ‎‡a  pathologyconsultationonthelaboratoryevaluationofthrombophilia‏ ‎‡A  Pathology Consultation on the Laboratory Evaluation of Thrombophilia‏ ‎‡9  1‏
919 ‎‡a  patientbloodmanagementasstandardofcare‏ ‎‡A  Patient Blood Management as Standard of Care‏ ‎‡9  1‏
919 ‎‡a  perceptionsaboutbloodtransfusionasurveyofsurgicalpatientsandtheiranesthesiologistsandsurgeons‏ ‎‡A  Perceptions about blood transfusion: a survey of surgical patients and their anesthesiologists and surgeons‏ ‎‡9  1‏
919 ‎‡a  periproceduralmanagementofpatientsonanticoagulants‏ ‎‡A  Periprocedural management of patients on anticoagulants‏ ‎‡9  1‏
919 ‎‡a  peroxiredoxin2recyclingisinhibitedduringerythrocytestorage‏ ‎‡A  Peroxiredoxin-2 recycling is inhibited during erythrocyte storage‏ ‎‡9  1‏
919 ‎‡a  phase2studyofdocetaxelplusenoxaparininchemotherapynaivepatientswithmetastaticnonsmallcelllungcancerpreliminaryresults‏ ‎‡A  Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results‏ ‎‡9  1‏
919 ‎‡a  photopheresisinsolidorgantransplantrejection‏ ‎‡A  Photopheresis in solid organ transplant rejection‏ ‎‡9  1‏
919 ‎‡a  plateletcountandprothrombintimehelpdistinguishthromboticthrombocytopenicpurpurahemolyticuremicsyndromefromdisseminatedintravascularcoagulationinadults‏ ‎‡A  Platelet count and prothrombin time help distinguish thrombotic thrombocytopenic purpura-hemolytic uremic syndrome from disseminated intravascular coagulation in adults‏ ‎‡9  1‏
919 ‎‡a  plateletsinduceneutrophilextracellulartrapsintransfusionrelatedacutelunginjury‏ ‎‡A  Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury‏ ‎‡9  1‏
919 ‎‡a  predictingstoragedependentdamagetoredbloodcellsusingnitriteoxidationkineticsperoxiredoxin2oxidationandhemoglobinandfreehememeasurements‏ ‎‡A  Predicting storage-dependent damage to red blood cells using nitrite oxidation kinetics, peroxiredoxin-2 oxidation, and hemoglobin and free heme measurements‏ ‎‡9  1‏
919 ‎‡a  predictorsofresponseandrelapseinacohortofadultswiththromboticthrombocytopenicpurpurahemolyticuremicsyndromeasingleinstitutionexperience‏ ‎‡A  Predictors of response and relapse in a cohort of adults with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: a single-institution experience‏ ‎‡9  1‏
919 ‎‡a  primarycarephysiciansandthelaboratorynowandthefuture‏ ‎‡A  Primary care physicians and the laboratory: now and the future‏ ‎‡9  1‏
919 ‎‡a  recommendationsforappropriateactivatedpartialthromboplastintimereagentselectionandutilization‏ ‎‡A  Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization‏ ‎‡9  1‏
919 ‎‡a  redbloodcellwashingnitritetherapyandantihemetherapiespreventstoredredbloodcelltoxicityaftertraumahemorrhage‏ ‎‡A  Red blood cell washing, nitrite therapy, and antiheme therapies prevent stored red blood cell toxicity after trauma-hemorrhage‏ ‎‡9  1‏
919 ‎‡a  refractorythrombocytopeniaandpositiveplateletcrossmatcheswithouthlaorplateletspecificantibodies‏ ‎‡A  Refractory thrombocytopenia and positive platelet crossmatches without HLA or platelet-specific antibodies‏ ‎‡9  1‏
919 ‎‡a  rejectionwithhemodynamiccompromiseobjectiveevidenceforefficacyofphotopheresis‏ ‎‡A  Rejection With Hemodynamic Compromise: Objective Evidence for Efficacy of Photopheresis‏ ‎‡9  1‏
919 ‎‡a  relapsesofthromboticthrombocytopenicpurpuraaftertreatmentwithrituximab‏ ‎‡A  Relapses of thrombotic thrombocytopenic purpura after treatment with rituximab‏ ‎‡9  1‏
919 ‎‡a  rhesusimmuneglobulindosingintheobesityepidemicera‏ ‎‡A  Rhesus Immune Globulin Dosing in the Obesity Epidemic Era‏ ‎‡9  1‏
919 ‎‡a  screeningwiththeactivatedprotein100resistanceassayyieldssignificantsavingsinapatientpopulationwithlowprevalenceoffactor5leiden‏ ‎‡A  Screening With the Activated Protein C Resistance Assay Yields Significant Savings in a Patient Population With Low Prevalence of Factor V Leiden‏ ‎‡9  1‏
919 ‎‡a  singlecenterexperiencewithextracorporealphotopheresisinpediatrichearttransplantation‏ ‎‡A  Single-center experience with extracorporeal photopheresis in pediatric heart transplantation‏ ‎‡9  1‏
919 ‎‡a  societyfortheadvancementofpatientbloodmanagementandanesthesiaandanalgesiaanewcollaborationandhomeforbloodmanagementresearch‏ ‎‡A  Society for the Advancement of Patient Blood Management and Anesthesia & Analgesia: A New Collaboration and Home for Blood Management Research‏ ‎‡9  1‏
919 ‎‡a  successfulpulmonarythromboendarterectomyinapatientwithsicklecelldiseasetreatedwithasinglepreoperativeredbloodcellexchange‏ ‎‡A  Successful pulmonary thromboendarterectomy in a patient with sickle cell disease treated with a single preoperative red blood cell exchange‏ ‎‡9  1‏
919 ‎‡a  teachingmedicalstudentsbasicprinciplesoflaboratorymedicine‏ ‎‡A  Teaching medical students basic principles of laboratory medicine‏ ‎‡9  1‏
919 ‎‡a  americansocietyforapheresisasfaispleasedtoofferaqualificationinapheresisqiainpartnershipwiththeboardofcertificationbocoftheamericansocietyforclinicalpathologyascpstartinginjanuaryof2016‏ ‎‡A  The American Society for Apheresis (ASFA) is pleased to offer a Qualification in Apheresis (QIA) in partnership with The Board of Certification (BOC) of the American Society for Clinical Pathology (ASCP) starting in January of 2016!‏ ‎‡9  1‏
919 ‎‡a  clinicalpathologistasconsultant‏ ‎‡A  The Clinical Pathologist as Consultant‏ ‎‡9  1‏
919 ‎‡a  isolatedprolongedptt‏ ‎‡A  The isolated prolonged PTT.‏ ‎‡9  1‏
919 ‎‡a  levelofcomplementactivationfragmentsishigherinredbloodcellunitsthansegments‏ ‎‡A  The level of complement activation fragments is higher in red blood cell units than segments‏ ‎‡9  1‏
919 ‎‡a  successofourpatientbloodmanagementprogramdependedonaninstitutionwidechangeintransfusionpractices‏ ‎‡A  The success of our patient blood management program depended on an institution-wide change in transfusion practices‏ ‎‡9  1‏
919 ‎‡a  thromboticmicroangiopathyregistryofnorthamericaaunitedstatesmultiinstitutionaltmanetwork‏ ‎‡A  The thrombotic microangiopathy Registry of North America: A United States multi-institutional TMA network‏ ‎‡9  1‏
919 ‎‡a  yieldofbonemarrowbiopsyandculturecomparedwithbloodcultureintheevaluationofhivinfectedpatientsformycobacterialandfungalinfections‏ ‎‡A  The yield of bone marrow biopsy and culture compared with blood culture in the evaluation of HIV-infected patients for mycobacterial and fungal infections.‏ ‎‡9  1‏
919 ‎‡a  therapeuticapheresisacademy2013beyondborders‏ ‎‡A  Therapeutic Apheresis Academy 2013: beyond borders‏ ‎‡9  1‏
919 ‎‡a  therapeuticplasmaexchangeforintractablepruritussecondarytoprimarysclerosingcholangitis‏ ‎‡A  Therapeutic plasma exchange for intractable pruritus secondary to primary sclerosing cholangitis‏ ‎‡9  1‏
919 ‎‡a  therapeuticplasmaexchangerapidlyimprovescardiacallograftfunctioninpatientswithpresumedantibodymediatedrejection‏ ‎‡A  Therapeutic plasma exchange rapidly improves cardiac allograft function in patients with presumed antibody-mediated rejection‏ ‎‡9  1‏
919 ‎‡a  thrombelastographicmeasuresofclotpropagationacomparisonofalphawiththemaximumrateofthrombusgeneration‏ ‎‡A  Thrombelastographic measures of clot propagation: a comparison of alpha with the maximum rate of thrombus generation‏ ‎‡9  1‏
919 ‎‡a  thromboticthrombocytopenicpurpura2012americansocietyforapheresisasfaconsensusconferenceonclassificationdiagnosismanagementandfutureresearch‏ ‎‡A  Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research‏ ‎‡9  1‏
919 ‎‡a  thromboticthrombocytopenicpurpuraandheparininducedthrombocytopenia2uniquecausesoflifethreateningthrombocytopenia‏ ‎‡A  Thrombotic thrombocytopenic purpura and heparin-induced thrombocytopenia: two unique causes of life-threatening thrombocytopenia‏ ‎‡9  1‏
919 ‎‡a  thromboticthrombocytopenicpurpuradoesnotshowseasonalvariationinalabama‏ ‎‡A  Thrombotic thrombocytopenic purpura does not show seasonal variation in Alabama‏ ‎‡9  1‏
919 ‎‡a  transfusionandpneumoniainthetraumaintensivecareunitanexaminationofthetemporalrelationship‏ ‎‡A  Transfusion and Pneumonia in the Trauma Intensive Care Unit: An Examination of the Temporal Relationship‏ ‎‡9  1‏
919 ‎‡a  transfusionmedicineillustratedmassivehemolysisduetothromboticthrombocytopenicpurpurainapatientwithaids‏ ‎‡A  Transfusion medicine illustrated. Massive hemolysis due to thrombotic thrombocytopenic purpura in a patient with AIDS.‏ ‎‡9  1‏
919 ‎‡a  transfusionmedicineillustratedsystemicneutrophilicaggregatesintransfusionrelatedacutelunginjury‏ ‎‡A  Transfusion medicine illustrated. Systemic neutrophilic aggregates in transfusion-related acute lung injury.‏ ‎‡9  1‏
919 ‎‡a  transfusionrelatedacutelunginjurypastpresentandfuture‏ ‎‡A  Transfusion-related acute lung injury: past, present, and future‏ ‎‡9  1‏
919 ‎‡a  transfusionsinthelessseverelyinjureddoesageoftransfusedbloodaffectoutcomes‏ ‎‡A  Transfusions in the Less Severely Injured: Does Age of Transfused Blood Affect Outcomes?‏ ‎‡9  1‏
919 ‎‡a  unusualthrombosesassociatedwithproteinsdeficiencyinpatientswithacquiredimmunodeficiencysyndromecasereportsandreviewoftheliterature‏ ‎‡A  Unusual thromboses associated with protein S deficiency in patients with acquired immunodeficiency syndrome: case reports and review of the literature‏ ‎‡9  1‏
919 ‎‡a  updateonextracorporealphotopheresisinheartandlungtransplantation‏ ‎‡A  Update on extracorporeal photopheresis in heart and lung transplantation‏ ‎‡9  1‏
919 ‎‡a  useofhydroxyethylstarchinleukocytapheresisproceduresdoesnotincreaserenaltoxicity‏ ‎‡A  Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity.‏ ‎‡9  1‏
919 ‎‡a  vonwillebranddiseaselaboratorydiagnosis‏ ‎‡A  von Willebrand Disease Laboratory Diagnosis‏ ‎‡9  1‏
919 ‎‡a  zikavirusandpatientbloodmanagement‏ ‎‡A  Zika Virus and Patient Blood Management‏ ‎‡9  1‏
919 ‎‡a  freeflapfailuresecondarytodualthrombophilia‏ ‎‡A  Free flap failure secondary to dual thrombophilia‏ ‎‡9  1‏
946 ‎‡a  a‏ ‎‡9  1‏
996 ‎‡2  ISNI|0000000040516993‏
996 ‎‡2  LC|n 97114654‏
996 ‎‡2  ISNI|0000000385771017‏
996 ‎‡2  PTBNP|1677099‏
996 ‎‡2  SUDOC|26749307X‏
996 ‎‡2  PTBNP|1090992‏
996 ‎‡2  ISNI|0000000081908192‏
996 ‎‡2  PTBNP|1403218‏
996 ‎‡2  ISNI|0000000030560886‏
996 ‎‡2  SUDOC|112640354‏
996 ‎‡2  DNB|14011436X‏
996 ‎‡2  DNB|1138663093‏
996 ‎‡2  RERO|A003564026‏
996 ‎‡2  PTBNP|283662‏
996 ‎‡2  BNC|981058529880006706‏
996 ‎‡2  PTBNP|1394749‏
996 ‎‡2  BNE|XX1464711‏
996 ‎‡2  RERO|A005726007‏
996 ‎‡2  ISNI|0000000070597552‏
996 ‎‡2  BLBNB|001463194‏
996 ‎‡2  PTBNP|1447093‏
996 ‎‡2  DNB|1172313334‏
996 ‎‡2  LC|no 96042790‏
996 ‎‡2  DNB|140552286‏
996 ‎‡2  PTBNP|1480254‏
996 ‎‡2  BNF|17700155‏
996 ‎‡2  PTBNP|1040863‏
996 ‎‡2  ISNI|000000003195756X‏
996 ‎‡2  BLBNB|000228409‏
996 ‎‡2  LC|nr 92025036‏
996 ‎‡2  ISNI|0000000067066531‏
996 ‎‡2  NKC|mub2015867924‏
996 ‎‡2  ISNI|0000000371245737‏
996 ‎‡2  ISNI|0000000069726505‏
996 ‎‡2  PTBNP|1691423‏
996 ‎‡2  LC|no 93003942‏
996 ‎‡2  ISNI|000000006859263X‏
996 ‎‡2  PTBNP|1447703‏
996 ‎‡2  PTBNP|1024138‏
996 ‎‡2  BNE|XX5041704‏
996 ‎‡2  RERO|A025700741‏
996 ‎‡2  PTBNP|698468‏
996 ‎‡2  NYNYRILM|128822‏
996 ‎‡2  NTA|131430971‏
996 ‎‡2  ISNI|000000007053480X‏
996 ‎‡2  NTA|32922042X‏
996 ‎‡2  ISNI|0000000068391694‏
996 ‎‡2  SUDOC|135486106‏
996 ‎‡2  ISNI|0000000069598101‏
996 ‎‡2  SUDOC|260493708‏
996 ‎‡2  PTBNP|109562‏
996 ‎‡2  PTBNP|1332200‏
996 ‎‡2  LC|n 2002101219‏
996 ‎‡2  SUDOC|252244885‏
996 ‎‡2  LC|n 90674836‏
996 ‎‡2  PTBNP|1917325‏
996 ‎‡2  PTBNP|1686372‏
996 ‎‡2  PTBNP|1706945‏
996 ‎‡2  PTBNP|1817588‏
996 ‎‡2  LC|n 95921299‏
996 ‎‡2  PTBNP|938446‏
996 ‎‡2  ISNI|000000007013235X‏
996 ‎‡2  PTBNP|183774‏
996 ‎‡2  PTBNP|1400593‏
996 ‎‡2  ISNI|0000000428268965‏
996 ‎‡2  PTBNP|59547‏
996 ‎‡2  BNF|13535932‏
996 ‎‡2  DNB|13192995X‏
996 ‎‡2  PTBNP|1356375‏
996 ‎‡2  PTBNP|813531‏
996 ‎‡2  ISNI|0000000050174966‏
996 ‎‡2  LC|n 85810000‏
996 ‎‡2  ISNI|0000000067787240‏
996 ‎‡2  ISNI|0000000439619476‏
996 ‎‡2  PTBNP|1356278‏
996 ‎‡2  SUDOC|256795568‏
996 ‎‡2  DNB|1158922183‏
996 ‎‡2  ISNI|0000000041342526‏
996 ‎‡2  PTBNP|1212517‏
996 ‎‡2  PTBNP|1452010‏
996 ‎‡2  BLBNB|001541861‏
996 ‎‡2  ISNI|0000000069812198‏
996 ‎‡2  ISNI|0000000096472571‏
996 ‎‡2  BNE|XX1068743‏
996 ‎‡2  ISNI|000000038865297X‏
996 ‎‡2  ISNI|0000000123579914‏
996 ‎‡2  NUKAT|n 2010169676‏
996 ‎‡2  PTBNP|81827‏
996 ‎‡2  ISNI|0000000078889779‏
996 ‎‡2  BNC|981059734478406706‏
996 ‎‡2  ISNI|0000000081212152‏
996 ‎‡2  PTBNP|954671‏
996 ‎‡2  PTBNP|1006860‏
996 ‎‡2  ISNI|0000000136192348‏
996 ‎‡2  SUDOC|127474234‏
996 ‎‡2  BNF|12922360‏
996 ‎‡2  PTBNP|201562‏
996 ‎‡2  PLWABN|9814034567105606‏
996 ‎‡2  RERO|A006249587‏
996 ‎‡2  SUDOC|103142924‏
996 ‎‡2  PTBNP|787153‏
996 ‎‡2  NUKAT|n 2014195839‏
996 ‎‡2  LC|no2007028095‏
996 ‎‡2  PTBNP|1452491‏
996 ‎‡2  PTBNP|1365970‏
996 ‎‡2  PTBNP|82671‏
996 ‎‡2  LC|n 96010710‏
996 ‎‡2  DNB|171501438‏
996 ‎‡2  PTBNP|1496910‏
996 ‎‡2  SUDOC|120763109‏
996 ‎‡2  LC|no2021056495‏
996 ‎‡2  PTBNP|1154768‏
996 ‎‡2  SUDOC|095277102‏
996 ‎‡2  PTBNP|1307099‏
996 ‎‡2  BNF|18055949‏
996 ‎‡2  ISNI|0000000070721584‏
996 ‎‡2  DNB|1057213586‏
996 ‎‡2  PTBNP|70020‏
996 ‎‡2  PTBNP|1342820‏
996 ‎‡2  NTA|181772833‏
996 ‎‡2  SELIBR|199292‏
996 ‎‡2  ISNI|0000000117145386‏
996 ‎‡2  DNB|1136341544‏
996 ‎‡2  PTBNP|242707‏
996 ‎‡2  ISNI|0000000077947594‏
996 ‎‡2  SUDOC|050659448‏
996 ‎‡2  PTBNP|1057662‏
996 ‎‡2  BNE|XX1651046‏
996 ‎‡2  ISNI|0000000069313962‏
996 ‎‡2  ISNI|0000000053117078‏
996 ‎‡2  BNF|14636728‏
996 ‎‡2  BLBNB|000289688‏
996 ‎‡2  ISNI|0000000070979016‏
996 ‎‡2  BLBNB|000504770‏
996 ‎‡2  NII|DA06870504‏
996 ‎‡2  ISNI|0000000033208351‏
996 ‎‡2  NSK|000539325‏
996 ‎‡2  ISNI|0000000068720566‏
996 ‎‡2  LC|no 95024135‏
996 ‎‡2  ISNI|0000000070295247‏
996 ‎‡2  ISNI|0000000069601729‏
996 ‎‡2  ISNI|0000000032433880‏
996 ‎‡2  NDL|01164953‏
996 ‎‡2  SUDOC|140808752‏
996 ‎‡2  BLBNB|000549068‏
996 ‎‡2  ISNI|0000000067679207‏
996 ‎‡2  BNE|XX1783875‏
996 ‎‡2  DNB|1172146950‏
996 ‎‡2  PTBNP|1276965‏
996 ‎‡2  PTBNP|1291057‏
996 ‎‡2  LC|n 2010201063‏
996 ‎‡2  LC|nb2014005322‏
996 ‎‡2  ISNI|0000000070838029‏
996 ‎‡2  ISNI|0000000078037496‏
996 ‎‡2  SUDOC|266275680‏
996 ‎‡2  ISNI|0000000070942440‏
996 ‎‡2  NSK|000636638‏
996 ‎‡2  ISNI|0000000378209712‏
996 ‎‡2  BLBNB|000240474‏
996 ‎‡2  LC|n 97095562‏
996 ‎‡2  LC|ns2012003736‏
996 ‎‡2  NTA|068742126‏
996 ‎‡2  SUDOC|058932674‏
996 ‎‡2  ISNI|000000006657995X‏
996 ‎‡2  DNB|1023468077‏
996 ‎‡2  ISNI|0000000069191811‏
996 ‎‡2  PTBNP|1423852‏
996 ‎‡2  PTBNP|174119‏
996 ‎‡2  BNE|XX890983‏
996 ‎‡2  J9U|987007605312305171‏
996 ‎‡2  BLBNB|001649201‏
996 ‎‡2  DNB|1013235088‏
996 ‎‡2  PTBNP|1051783‏
996 ‎‡2  ISNI|0000000070927603‏
996 ‎‡2  PTBNP|1007488‏
996 ‎‡2  LC|nr2006027754‏
996 ‎‡2  BLBNB|001459082‏
996 ‎‡2  PTBNP|1443668‏
996 ‎‡2  LC|no2023014143‏
996 ‎‡2  BNF|15006433‏
996 ‎‡2  PLWABN|9810561836505606‏
996 ‎‡2  PTBNP|912705‏
996 ‎‡2  PTBNP|1341879‏
996 ‎‡2  SUDOC|074075160‏
996 ‎‡2  PTBNP|1419468‏
996 ‎‡2  ISNI|000000007029683X‏
996 ‎‡2  DNB|1220301485‏
996 ‎‡2  ISNI|0000000118782782‏
996 ‎‡2  DNB|1157302106‏
996 ‎‡2  LC|no2024116033‏
996 ‎‡2  BLBNB|000289777‏
996 ‎‡2  DNB|1057610062‏
996 ‎‡2  BLBNB|000289773‏
996 ‎‡2  ISNI|0000000075129213‏
996 ‎‡2  BNE|XX4909349‏
996 ‎‡2  ISNI|0000000077869987‏
996 ‎‡2  ISNI|0000000079231012‏
996 ‎‡2  ISNI|0000000069287485‏
996 ‎‡2  ISNI|0000000114605375‏
996 ‎‡2  CAOONL|ncf11895262‏
996 ‎‡2  SUDOC|15566347X‏
996 ‎‡2  DBC|870979137714078‏
996 ‎‡2  ISNI|0000000068605568‏
996 ‎‡2  LC|no2016162589‏
996 ‎‡2  PTBNP|27768‏
996 ‎‡2  LC|nr 97042698‏
996 ‎‡2  BAV|495_83253‏
996 ‎‡2  BNF|11886926‏
996 ‎‡2  SUDOC|122647351‏
996 ‎‡2  PTBNP|1563509‏
996 ‎‡2  SUDOC|258557435‏
996 ‎‡2  ISNI|0000000068907806‏
996 ‎‡2  PTBNP|1323443‏
996 ‎‡2  BLBNB|000289755‏
996 ‎‡2  LC|n 85058217‏
996 ‎‡2  DNB|132675897‏
996 ‎‡2  ISNI|0000000070523895‏
996 ‎‡2  LC|n 2015238166‏
996 ‎‡2  PTBNP|1156814‏
996 ‎‡2  LC|n 2008078568‏
996 ‎‡2  BNC|981058523166706706‏
996 ‎‡2  LC|no2014040539‏
996 ‎‡2  PTBNP|1492513‏
996 ‎‡2  ISNI|0000000038777713‏
996 ‎‡2  ISNI|0000000111538453‏
996 ‎‡2  ISNI|0000000069079969‏
996 ‎‡2  PTBNP|1667719‏
996 ‎‡2  ISNI|0000000044344340‏
996 ‎‡2  ISNI|0000000067662608‏
996 ‎‡2  DNB|1053087454‏
996 ‎‡2  ISNI|0000000070513849‏
996 ‎‡2  DNB|105750176X‏
996 ‎‡2  PTBNP|961317‏
996 ‎‡2  BNE|XX4580449‏
996 ‎‡2  BLBNB|000587853‏
996 ‎‡2  BNE|XX4856251‏
996 ‎‡2  PTBNP|1880399‏
996 ‎‡2  DNB|1060681374‏
996 ‎‡2  SUDOC|111511828‏
996 ‎‡2  LC|n 90675599‏
996 ‎‡2  PTBNP|334330‏
996 ‎‡2  PTBNP|1261555‏
996 ‎‡2  LC|n 2010202882‏
996 ‎‡2  BLBNB|000157461‏
996 ‎‡2  LC|no2011196091‏
996 ‎‡2  PTBNP|1811416‏
996 ‎‡2  ISNI|0000000409939655‏
996 ‎‡2  ISNI|0000000070031794‏
996 ‎‡2  PTBNP|1245327‏
996 ‎‡2  ISNI|0000000114532129‏
997 ‎‡a  0 0 lived 0 0‏ ‎‡9  1‏